Get App

Co-Partners

Associate Partners

Last Updated : Apr 26, 2019 11:22 AM IST | Source: PTI

USFDA makes 'certain' observations for Torrent Pharma's Indrad plant

As per the USFDA, an "FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts".

Representative image
Representative image
 
 
live
  • bselive
  • nselive
Volume
Todays L/H
More

Drug firm Torrent Pharmaceuticals on Friday said the US health regulator has made 'certain' observations after inspection of its Indrad facility in Gujarat. The audit at Indrad plant of the company was carried out by the United States Food and Drug Administration (USFDA) in April.

"We have received certain observations which are procedural in nature and the company is confident of addressing them satisfactorily," Torrent Pharmaceuticals said in a BSE filing.

The company, however, did not quantify how many observations were made by the US health regulator.

As per the USFDA, an "FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgement may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts".

It notifies the company's management of objectionable conditions.

Shares of Torrent Pharmaceuticals were trading 1.51 per cent higher at Rs 1,754 apiece on BSE.
First Published on Apr 26, 2019 11:15 am
More From
Loading...
Sections
Follow us on
Available On
PCI DSS Compliant